IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 showed enhanced potency and […]
Autor: Firma immatics biotechnologies
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced […]
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) […]
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402 Cash and cash equivalents as […]
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model IMA402 targets an Immatics–validated peptide derived from PRAME, one of the most frequently expressed intracellular cancer targets for TCR therapy Immatics has selected a clinical lead candidate for the IMA402 program and initiated manufacturing activities Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage […]
Immatics Announces Full Year 2020 Financial Results and Corporate Update
Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine® IMA200 trial series continues […]
Immatics Announces Third Quarter 2020 Financial Results and Business Update
ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose escalation is on track for Q1 2021 Expansion of UTHealth partnership secures cell therapy manufacturing […]
Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
<p> </p> <ul type="disc"> <li>Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence.</li> <li>Clinical courses observed in patients indicate COL6A3 […]
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics The IMA401 target, an HLA-A*02-bound peptide derived both […]
Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the appointment of Eliot Forster, PhD, to […]